Assessment and Clinical Implications of Cardioselectivity by Dr J L Wale and Dr J D Fitzgerald (ICI Pharmaceuticals Division, Alderley Park, Cheshire) All the beta-blocking drugs currently available for clinical use are competitive antagonists of beta-receptors. Increasing doses of isoprenaline induce progressive relaxation of e.g. calf tracheal muscle. In the presence of increasing concentrations of propranolol higher and higher doses of isoprenaline have to be used to produce the same effect. Fuithermore, the maximum effect is not altered, and this is basically what is meant by competitive antagonism. A receptor is a purely hypothetical concept, being a molecular constituent of effector cells with which catecholamines interact in order to produce a response. The concept of a specific receptor for drug interaction bestows specificity of drug effect, and betablockers will only abolish the positive inotropic action of isoprenaline, but do not reduce that produced by calcium, glucagon or a cardiac glycoside such as acetylstrophanthidin, whose action depends on some other reaction with the cardiac membrane. A specific antagonism of the adrenergic receptors implies antagonism solely of catecholamine-mediated cellular effects. Beta receptors are widespread and can be divided into two types, beta, and beta2, with some others which cannot be categorized (Fig 1) . The ones which are most important clinically are the cardiac beta-receptor and, as an adverse effect, the bronchial beta-receptor although other receptors, for example those controlling FFA production, glycogenolysis, platelets and renin, may also have a role to play in clinical use. Selectivity of certain beta stimulants or betablocking drugs implies the apparent ability of such drugs to differentiate between the different types of beta-receptors. This can be clearly demonstrated again in animal experiments. Clinical Implications ofCardioselectivity The relative lack of effect on respiratory function of a cardioselective beta-blocker in the doses required for antihypertensive activity is of immediate importance in the treatment of patients with obstructive airways disease. A cardioselective beta-blocking drug also enables the full benefit of a beta-adrenergic bronchodilator such as isoprenaline to be exerted so that full relaxation of the bronchial smooth muscle is available, even in the presence of atenolol. On the other hand, a nonselective drug has an effect on the resting respiratory function and also abolishes beneficial effects of the beta-adrenergic bronchodilator. The clinical implications of lack of effect of a cardioselective beta-blocking drug on peripheral vascular beta-receptors are less easy to define. (1972) showed that on acute i.v. administration of propranolol there was a reduction in cardiac index, in heart rate, but also a.rise in total peripheral resistance (Fig 4) . The rise in total peripheral resistance is due firstly to a reflex alpha-adrenergic vasoconstriction, as a result of the fall in cardiac index. It may also have been contributed to by blockade of peripheral vascular beta-receptors. A cardioselective betablocking drug may also reduce cardiac index in the same way as propranolol, but it does not antagonize the peripheral beta-receptors. Astrom & Vallin (1974) were able to show that in angina patients propranolol and atenolol both reduced cardiac output at rest and during exercise ( Fig 5) .
With both drugs there is a reduction in cardiac output indicated by the shift to the right at rest and during exercise. However, propranolol does not reduce aortic pressure at rest or during exercise, whereas atenolol, interestingly, reduced aortic blood pressure during exercise. Atenolol also tended to produce a greater increase in maximum work achieved, as compared with nropranolol at the same maximum heart rate.
Beta adrenoceptors are also present in the coronary circulation, and results from experiments in anesthetized dogs suggest that these receptors resemble peripheral vascular beta receptors. Dogs were given two doses of isoprenaline (0.04 ,ug and 0.4 ,ug). The lower dose produced an increase in coronary flow with no increase in cardiac contractile force, while the higher dose produced a marked increase in coronary flow plus an increase in cardiac contractile force. After a cardioselective beta-blocking drug such as practolol, the lower dose of isoprenaline could still produce an increase in coronary flow. The higher dose of isoprenaline no longer produced an increase in cardiac contractile activity and there was some apparent reduction in the coronary flow response. However, it is important to remember that the hemodynamics (activity of the heart), as well as the local myocardial metabolic activity, have an important role in controlling coronary circulation, so a lot of this reduction in coronary flow, rather than being the result of blockade of the coronary beta-receptors, is secondary to the abolition of the positive inotropic effect.
Conclusion
The clinical implications of the lack of effect of a cardioselective beta-blocking drug on respiratory function are clear cut. The clinical relevance of the lack of blockade on vascular beta-receptors with a cardioselective beta-blocking drug warrants further investigation, although the consequent benefits of such a lack of effect may be small.
